当前位置： SCI文献检索 > CLINICAL PHARMACOKINETICS期刊下所有文献 > Relevance of absorption rate and lag time to the onset of action in migraine.

Relevance of absorption rate and lag time to the onset of action in migraine.

Abstract：

OBJECTIVE:The objective of this analysis was to simulate the performance of oral triptan formulations with varying absorption characteristics and their impact on the onset and magnitude of the antimigraine effect using a Markov model for migraine attacks. ANALYSIS:Sumatriptan pharmacokinetic data were obtained from clinical pharmacology studies in which marketed solid formulations were administered. Based on a population pharmacokinetic model, mean concentration-time profiles were generated by varying the absorption rate constant and lag time. Subsequently, the simulated profiles were evaluated in a disease model of migraine to predict the onset and duration of the effect (the pain-free, pain-relief response). RESULTS:Based on a therapeutic dose of 50 mg of sumatriptan, a maximum gain in the pain-free response of 12% was achieved with an increased absorption rate. This gain in the response was reached approximately 0.5 hours after administration. A decrease only in the lag time with respect to the currently available formulations (i.e. 0.24 hours) resulted in a maximum gain of 5% in the pain-free response, which in contrast may not be interpreted as clinically relevant. CONCLUSION:Model-based predictions suggest that increases in the absorption rate of the currently marketed oral formulation of sumatriptan result in a gain in the pain-free response that is both clinically and statistically relevant.

journal_name

Clin Pharmacokinet

journal_title

Clinical pharmacokinetics

authors

Maas HJ,Spruit MA,Danhof M,Della Pasqua OE

doi

10.2165/00003088-200847020-00007

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

139-46

issue

2

eissn

0312-5963

issn

1179-1926

pii

4727

journal_volume

47

pub_type

杂志文章

相关文献

CLINICAL PHARMACOKINETICS文献大全
  • Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

    abstract：BACKGROUND AND OBJECTIVE:Febuxostat is a xanthine oxidase inhibitor indicated for gout and hyperuricemia. This work investigates potential clinically relevant covariates for febuxostat pharmacokinetics with a special focus on Asian race and bodyweight. METHODS:Febuxostat plasma concentrations from 141 male subjects we...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-020-00943-6

    authors： Rekić D,Johansson S,Leander J

    更新日期：2020-09-19 00:00:00

  • Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

    abstract：:Hydroxymetabolites of the antidepressants nortriptyline and desipramine, like the parent drugs, inhibit neuronal uptake of noradrenaline (norepinephrine). In both plasma and cerebrospinal fluid (CSF), the concentrations of the 10-hydroxymetabolites of nortriptyline (10-OH-NT) are usually higher than those of the paren...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199528010-00004

    authors： Nordin C,Bertilsson L

    更新日期：1995-01-01 00:00:00

  • An Extension of Janmahasatian's Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities.

    abstract：BACKGROUND:Fat-free mass (FFM)-based dose scaling is increasingly being adopted in clinical pharmacology. Given the complexities with the measurement of FFM in clinical practice, choosing an appropriate equation for FFM is critical for accurate dose scaling. Janmahasatian's FFM model (FFMJan) has largely remained the p...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-020-00883-1

    authors： Sinha J,Al-Sallami HS,Duffull SB

    更新日期：2020-09-01 00:00:00

  • Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.

    abstract：BACKGROUND:Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries. Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are available regarding pharmacokinetics and especially population pharmacokinetics. PATIENTS AND METHO...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200948030-00003

    authors： Royer B,Jullien V,Guardiola E,Heyd B,Chauffert B,Kantelip JP,Pivot X

    更新日期：2009-01-01 00:00:00

  • Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

    abstract：BACKGROUND AND OBJECTIVES:NXY-059 (disufenton sodium, Cerovive, a nitrone with neuroprotective and free radical trapping properties (in experimental stroke) is under development for the treatment of acute stroke. The objectives of this study were to develop a population pharmacokinetic model for NXY-059 in acute stroke...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.2165/00003088-200544080-00007

    authors： Jönsson S,Cheng YF,Edenius C,Lees KR,Odergren T,Karlsson MO

    更新日期：2005-01-01 00:00:00

  • Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

    abstract：:Despite contributing significantly to the burden of global disease, the translation of new treatment strategies for diseases of the central nervous system (CNS) from animals to humans remains challenging, with a high attrition rate in the development of CNS drugs. The failure of clinical trials for CNS therapies can b...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1007/s40262-018-0632-y

    authors： Srinivas N,Maffuid K,Kashuba ADM

    更新日期：2018-09-01 00:00:00

  • Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.

    abstract：BACKGROUND:Because of the vulnerability and frailty of elderly adults, clinical drug development has traditionally been biased towards young and middle-aged adults. Recent efforts have begun to incorporate data from paediatric investigations. Nevertheless, the elderly often remain underrepresented in clinical trials, e...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-016-0422-3

    authors： Schlender JF,Meyer M,Thelen K,Krauss M,Willmann S,Eissing T,Jaehde U

    更新日期：2016-12-01 00:00:00

  • Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers.

    abstract：OBJECTIVE:To assess the dose proportionality of lacidipine after single and repeated oral doses, and to obtain new information on the pharmacokinetics of the compound since improvement of the plasma assay method. DESIGN:Open, randomised, four-way cross-over trial. PARTICIPANTS:24 healthy male and female volunteers, a...

    journal_title：Clinical pharmacokinetics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.2165/00003088-200342010-00004

    authors： Da Ros L,Squassante L,Milleri S

    更新日期：2003-01-01 00:00:00

  • A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.

    abstract：BACKGROUND:Peripherally acting opioids, particularly peripheral κ-opioid agonists, may be effective for treating visceral pain by activating receptors expressed on afferent nerves within the gut. OBJECTIVE:The objective of this study was to investigate the pharmacokinetic/pharmacodynamic profile of a novel peripherall...

    journal_title：Clinical pharmacokinetics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s40262-012-0023-8

    authors： Olesen AE,Kristensen K,Staahl C,Kell S,Wong GY,Arendt-Nielsen L,Drewes AM

    更新日期：2013-02-01 00:00:00

  • Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

    abstract：:Antibiotic therapy is one of the main treatments for cystic fibrosis (CF). It aims to eradicate bacteria during early infection, calms down the inflammatory process, and leads to symptom resolution of pulmonary exacerbations. CF can modify both the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of antibiotics,...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1007/s40262-020-00981-0

    authors： Magréault S,Roy C,Launay M,Sermet-Gaudelus I,Jullien V

    更新日期：2021-01-24 00:00:00

  • Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.

    abstract：INTRODUCTION:Renal impairment may have a significant impact on the pharmacokinetics of drugs. Ad hoc studies in subjects with renal impairment are required by the regulatory authorities to propose dose adjustments in these subjects, to find a dosing regimen able to provide a systemic exposure similar to those in subjec...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-017-0574-9

    authors： Borella E,Poggesi I,Magni P

    更新日期：2018-04-01 00:00:00

  • Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.

    abstract：BACKGROUND AND OBJECTIVE:Genetic polymorphisms of cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, however, the factors associate...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40262-012-0009-6

    authors： Ichimura Y,Takahashi H,Lee MT,Shiomi M,Mihara K,Morita T,Chen YT,Echizen H

    更新日期：2012-12-01 00:00:00

  • Cyclosporin clinical pharmacokinetics.

    abstract：:Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. It is a lipophilic molecule, with its bioavailability dependent on food, bile and other interacting factors. Cyclosporin is extensively metabolised in the liver by the cytochrome P450 3A system, which is...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199324060-00004

    authors： Fahr A

    更新日期：1993-06-01 00:00:00

  • Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.

    abstract：:The combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients with extensive liver metastases and prior treatment. Systemic exposure to the drugs or their main metabolites was determined dur...

    journal_title：Clinical pharmacokinetics

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s40262-016-0431-2

    authors： Lévi F,Karaboué A,Etienne-Grimaldi MC,Paintaud G,Focan C,Innominato P,Bouchahda M,Milano G,Chatelut E

    更新日期：2017-02-01 00:00:00

  • Clinical pharmacokinetics of fluvoxamine.

    abstract：:Fluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression. Following oral administration, the drug is absorbed efficiently from the gastrointestinal tract. Peak plasma concentrations are usually observed within 2 to 8 hours postdose for capsules and film-coated tabl...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199427030-00002

    authors： Perucca E,Gatti G,Spina E

    更新日期：1994-09-01 00:00:00

  • Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy.

    abstract：OBJECTIVE:To analyse the influence of covariates on the apparent clearance (CL) of tacrolimus in paediatric liver transplant recipients being converted from cyclosporin to tacrolimus. DESIGN:Retrospective modelling study. PATIENTS AND PARTICIPANTS:18 children, 13 girls and 5 boys, aged 4 months to 16 years (median 9....

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200140010-00005

    authors： García Sánchez MJ,Manzanares C,Santos-Buelga D,Blázquez A,Manzanares J,Urruzuno P,Medina E

    更新日期：2001-01-01 00:00:00

  • Clinical pharmacokinetics of pravastatin.

    abstract：:The hypolipidaemic agent pravastatin differs from other US Food and Drug Administration (FDA)-approved HMG-CoA reductase inhibitors (e.g. lovastatin and simvastatin) because it has greater hydrophilicity, as a result of the hydroxyl group attached to its decalin ring. The hydrophilic nature of pravastatin accounts for...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199427020-00002

    authors： Quion JA,Jones PH

    更新日期：1994-08-01 00:00:00

  • Pharmacokinetic drug interactions of commonly used anticancer drugs.

    abstract：:With the use of combination chemotherapy as well as a wide range of symptomatic therapies (e.g. analgesics and antiemetics) for the treatment of patients with cancer, the field of oncology practises polypharmacy to an extreme degree. The risk for a drug interaction under these conditions is high, and the pharmacologic...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198611030-00004

    authors： Balis FM

    更新日期：1986-05-01 00:00:00

  • Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.

    abstract：:Alemtuzumab is a humanized monoclonal antibody against CD52 and causes depletion of T and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment of multiple sclerosis (MS) and is also used in chronic lymphocytic leukemia (CLL). Alemtuzumab is used off-label in kidney transplantation as ind...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-017-0573-x

    authors： van der Zwan M,Baan CC,van Gelder T,Hesselink DA

    更新日期：2018-02-01 00:00:00

  • Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?

    abstract：:Adequate immunosuppression minimising the risk of organ rejection with acceptable tolerability of the used drugs is a crucial step in organ transplantation. The primary goal is to maintain a consistent time-dependent target concentration by tailoring individual dosage leading to the best efficacy and tolerability comb...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200241050-00001

    authors： Mourad M,Wallemacq P,König J,de Frahan EH,Eddour DC,De Meyer M,Malaise J,Squifflet JP

    更新日期：2002-01-01 00:00:00

  • Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

    abstract：BACKGROUND:International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for better understanding of the influence of ethnicity on drug response to minimize duplication of clinical studies, thereby expediting drug approval. OBJ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-013-0089-y

    authors： Barter ZE,Tucker GT,Rowland-Yeo K

    更新日期：2013-12-01 00:00:00

  • Clinical pharmacokinetics of dorzolamide.

    abstract：:Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and the...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200241030-00004

    authors： Martens-Lobenhoffer J,Banditt P

    更新日期：2002-01-01 00:00:00

  • Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

    abstract：:Clinical pharmacokinetics emerged as a clinical discipline in the late 1960s and early 1970s. Clinical pharmacokinetic monitoring (CPM) helped many pharmacists to enter the clinical arena, but the focus was more on the pharmacists and tools. With the widespread acceptance of pharmaceutical care and patient-focused pha...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199834040-00001

    authors： Ensom MH,Davis GA,Cropp CD,Ensom RJ

    更新日期：1998-04-01 00:00:00

  • Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease.

    abstract：:Following administration of equivalent oral doses (30mg) of either prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by prednisone, and 7 healthy volunteers, corticosteroid concentrations we...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198207050-00005

    authors： Uribe M,Summerskill WH,Go VL

    更新日期：1982-09-01 00:00:00

  • Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

    abstract：BACKGROUND AND OBJECTIVES:The likelihood of detecting a therapeutic signal of an effective drug for schizophrenia is impeded by a high placebo effect and by high dropout of patients. Several unsuccessful trials of schizophrenia, at least partly due to highly variable placebo effects, have indicated the necessity for a ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/11598460-000000000-00000

    authors： Pilla Reddy V,Kozielska M,Johnson M,Suleiman AA,Vermeulen A,Liu J,de Greef R,Groothuis GM,Danhof M,Proost JH

    更新日期：2012-04-01 00:00:00

  • Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.

    abstract：:Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. They are proposed as a novel approach for the management of type 2 diabetes mellitus. They have proven their efficacy in reducing glycated haemoglobin...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1007/s40262-013-0128-8

    authors： Scheen AJ

    更新日期：2014-04-01 00:00:00

  • Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations.

    abstract：:The pharmacokinetics of dothiepin were evaluated in 9 depressed patients following a single oral dose of 75 mg. Blood and plasma concentrations of dothiepin and 2 major metabolites, northiaden and dothiepin S-oxide, were measured by gas chromatography/mass fragmentography. The mean (+/-SD) peak plasma concentrations o...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198308020-00004

    authors： Maguire KP,Norman TR,McIntyre I,Burrows GD

    更新日期：1983-03-01 00:00:00

  • Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.

    abstract：OBJECTIVE:The objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered either as crushed (in the semi-upright sitting position) or as integral (in the supine position) tablets in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percu...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40262-015-0320-0

    authors： Alexopoulos D,Barampoutis N,Gkizas V,Vogiatzi C,Tsigkas G,Koutsogiannis N,Davlouros P,Hahalis G,Nylander S,Parodi G,Xanthopoulou I

    更新日期：2016-03-01 00:00:00

  • Reliability of antiarrhythmic drug plasma concentration monitoring.

    abstract：:Measurement of drug levels is becoming increasingly popular to optimise the dosage of various drugs. In the case of antiarrhythmic drugs, the narrow therapeutic margin of most of these agents and a direct relationship between their pharmacological effects and plasma concentrations would justify more widespread use of ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198308010-00004

    authors： Follath F,Ganzinger U,Schuetz E

    更新日期：1983-01-01 00:00:00

  • Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

    abstract：OBJECTIVE:To explore the ability of the nonparametric expectation maximisation (NPEM) method of population pharmacokinetic modelling to deal with sparse data in estimating systemic caffeine clearance for monitoring and evaluation of cytochrome P450 (CYP) 1A2 activity. DESIGN AND PARTICIPANTS:Nonblind, single-dose clin...

    journal_title：Clinical pharmacokinetics

    pub_type： 临床试验,杂志文章

    doi：10.2165/00003088-200342150-00006

    authors： Terziivanov D,Bozhinova K,Dimitrova V,Atanasova I

    更新日期：2003-01-01 00:00:00